Author: Rune Skeie
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
March 9, 2023
- Global trial designed to study the safety, tolerability and efficacy of bemcentinib in combination…
Read MoreBerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update
February 16, 2023
BERGEN, Norway, February 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing…
Read More
BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients
February 15, 2023
- The Company will discuss the topline results during its Q4 2022 results presentation on…
Read MoreBerGenBio Announces the Establishment of Oncology Scientific Advisory Board
February 2, 2023
- Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC - BERGEN, Norway,…
Read MoreBerGenBio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 15, 2022
- Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients --…
Read MoreBerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations
October 11, 2022
- Study will assess bemcentinib in combination with current standard of care for 1st line…
Read More
